Relapsed/refractory primary central nervous system lymphoma research hub

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma

This study is for people with a type of brain lymphoma that has come back or not responded to previous treatment. It compares a new medicine, Tirabrutinib, with standard treatments (Rituximab and Temozolomide) to see which is better at stopping the cancer from growing.